Nilai, Negeri Sembilan, Malaysia Related Funds
| Fund Name | Location |
| Applied Research Council | China, Hong Kong, Hong Kong Island |
| Axon Ventures | California, San Diego, United States |
| Beijing Shixi Yutang Huachuang Investment Management | Beijing, Beijing, China |
| Cambridge University Press | - |
| D3 Jubilee | Seoul, Seoul-t'ukpyolsi, South Korea |
| Digital China | Beijing, China, Haidian |
| Eminence Capital LP | New York, New York, United States |
| Foreign Investment Promotion Board | - |
| Fox Interactive Media | Beverly Hills, California, United States |
| Fujian Huamin Industry Group | China, Foochow, Fujian |
| Kansas City Equity Partners | Kansas City, Missouri, United States |
| Lumen Ventures | England, London, United Kingdom |
| MRCF Biomedical Translation Fund | - |
| National Bank of Canada | NAventures | Canada, Montréal, Quebec |
| Potent Assets | China, Hong Kong, Hong Kong Island |
| Select Trade Investment Management | China, Shanghai |
| Sridham Enterprises | - |
| Transference Fund | China, Shanghai |
| University Venture Fund | Salt Lake City, United States, Utah |
| Victory Capital | Brooklyn, Ohio, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
ENYO Pharma | $47M | 04 Jun 2018 | Lyon, Auvergne-Rhône-Alpes, France | ||
MedDay | $38M | 08 Apr 2016 | France, Ile-de-France |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
ENYO Pharma | $47M | 04 Jun 2018 | Lyon, Auvergne-Rhône-Alpes, France | ||
MedDay | $38M | 08 Apr 2016 | France, Ile-de-France |
